Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010.

@article{Yu2012PeramivirUF,
  title={Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009-June 2010.},
  author={Yon C Yu and Shikha Garg and Patricia A. Yu and Hye-Joo Kim and Anita Patel and Toby L. Merlin and Stephen C. Redd and Timothy M Uyeki},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2012},
  volume={55 1},
  pages={
          8-15
        }
}
  • Yon C Yu, S. Garg, +5 authors T. Uyeki
  • Published 2012
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
BACKGROUND In response to the influenza A(H1N1)pdm09 (pH1N1) pandemic, peramivir, an investigational intravenous neuraminidase inhibitor, was made available for treatment of hospitalized patients with pH1N1 in the United States under an Emergency Use Authorization (EUA). The Centers for Disease Control and Prevention (CDC) implemented a program to manage peramivir distribution to requesting clinicians under EUA. We describe results of the CDC's peramivir program and 3 related surveys. METHODS… Expand
Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus.
  • A. Sorbello, S. Jones, +14 authors G. D. Dal Pan
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2012
TLDR
The safety data were insufficient to assess whether peramivir affected outcome or caused adverse reactions other than rash, and clinical trials in hospitalized patients with serious influenza infections should provide additional information. Expand
Safety and efficacy of peramivir for influenza treatment
TLDR
Peramivir shows efficacy for the treatment of seasonal and pH1N1 influenza, and might be a beneficial alternative antiviral treatment for many patients, including those unable to receive inhaled or oral neuraminidase inhibitors, or those requiring nonintravenous drug delivery. Expand
Editorial commentary: What did we learn from the emergency use authorization of peramivir in 2009?
  • A. Pavia
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2012
TLDR
Two articles in this issue describe the available data from the experience and leave many questions unanswered about the efficacy, safety, and impact of peramivir on pH1N1 infection. Expand
Peramivir is as effective as oral oseltamivir in the treatment of severe seasonal influenza
TLDR
Peramivir has the similar clinical efficacy to oseltamivIR in the treatment of severe seasonal influenza in the critically ill patients admitted to ICU. Expand
Peramivir: A Novel Intravenous Neuraminidase Inhibitor for Treatment of Acute Influenza Infections
TLDR
Successful clinical trials and post-marketing data in pediatric populations in Japan support the safety and efficacy of peramivir in this population where administration of other antivirals might not be feasible. Expand
Peramivir injection in the treatment of acute influenza: a review of the literature
TLDR
Although anecdotal evidence supports the use of peramivir in pediatric patients, pregnant women, and hospitalized patients with severe influenza receiving continuous renal replacement therapy and extracorporeal membrane oxygenation, well-designed, controlled clinical trials should be conducted in order to assess its clinical efficacy in these patient populations. Expand
Emergency authorization of medical products: regulatory challenges from the 2009 H1N1 influenza pandemic in Japan.
TLDR
The different regulatory approaches of Japan and the United States, countries with advanced regulatory and healthcare systems, to emergency authorization of the use of medical products as a countermeasure to public health emergencies are comprehensively reviewed. Expand
Effects of corticosteroid and neuraminidase inhibitors on survival in patients with respiratory distress induced by influenza virus.
TLDR
Salvage peramivir provided a better prognosis than monotherapy with oseltamivIR in patients who were infected with H1pdm09 or type B virus and who developed respiratory distress and a systemic corticosteroid should be administered after initiating NAI therapy, especially in patients with chronic lung disease. Expand
European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL‐4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN
TLDR
A review of ECIL‐4's main recommendations for prevention and management of influenza infections in leukemia patients and hematopoietic stem cell transplantation recipients concludes that neuraminidase inhibitors are currently the most effective therapeutic agents for influenza. Expand
Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.
  • T. Uyeki, H. Bernstein, +15 authors A. Pavia
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2019
TLDR
These clinical practice guidelines are an update of the guidelines published by the Infectious Diseases Society of America in 2009 and address new information regarding diagnostic testing, treatment and chemoprophylaxis with antiviral medications, and issues related to institutional outbreak management for seasonal influenza. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 21 REFERENCES
Emergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus.
  • A. Sorbello, S. Jones, +14 authors G. D. Dal Pan
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2012
TLDR
The safety data were insufficient to assess whether peramivir affected outcome or caused adverse reactions other than rash, and clinical trials in hospitalized patients with serious influenza infections should provide additional information. Expand
Efficacy, Safety, and Pharmacokinetics of Intravenous Peramivir in Children with 2009 Pandemic H1N1 Influenza A Virus Infection
TLDR
Peramivir exposure in children was within the range of levels within which the efficacy and safety was confirmed in adults, and it is considered that peramivIR is clinically and virologically effective and safe in children with pH1N1 virus infection. Expand
Intravenous Peramivir for Treatment of Influenza A and B Virus Infection in High-Risk Patients
TLDR
Intravenous peramivir appears to offer a potentially useful treatment for high-risk patients in the future, and the duration of influenza illness was significantly shorter in the 600-mg group than in the 300-mg groups. Expand
Losing the opportunity to study influenza drugs.
TLDR
The authors recognized that their retrospective analysis of oseltamivir did not provide definitive information about this agent, and they concluded that independent randomized trials to resolve these uncertainties are needed. Expand
Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010).
  • S. Shrestha, D. Swerdlow, +18 authors M. Meltzer
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2011
TLDR
In this study, adults 65 years of age or older were found to have rates of hospitalization and death that were up to 75% and 81%, respectively, lower than seasonal influenza, and this results confirm the necessity of a concerted public health response to pH1N1. Expand
Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza
TLDR
Oseltamivir was well absorbed enterically in critically ill patients admitted to the ICU with suspected or confirmed pandemic (H1N1) influenza and adjustment of the dosage in patients with renal dysfunction requiring continuous renal replacement therapy is appropriate; adjustment for obesity does not appear to be necessary. Expand
Clinical Experience in Adults and Children Treated with Intravenous Peramivir for 2009 Influenza A (H1N1) Under an Emergency IND Program in the United States
Peramivir, an investigational intravenous neuraminidase inhibitor, was given to 31 hospitalized patients with severe viral pneumonia during the 2009 H1N1 influenza pandemic under the Emergency INDExpand
The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza.
On October 23 the FDA issued an Emergency Use Authorization for peramivir for the treatment of suspected or confirmed cases of 2009 H1N1 influenza. Drs. Debra Birnkrant and Edward Cox discuss theExpand
Emergence of a novel swine-origin influenza A (H1N1) virus in humans.
TLDR
A novel swine-origin influenza A virus was identified as the cause of outbreaks of febrile respiratory infection ranging from self-limited to severe illness and it is likely that the number of confirmed cases underestimates thenumber of cases that have occurred. Expand
Efficacy and Safety of Intravenous Peramivir for Treatment of Seasonal Influenza Virus Infection
TLDR
A single intravenous dose of peramivir is effective and well tolerated in subjects with uncomplicated seasonal influenza virus infection and significantly reduced the time to alleviation of symptoms at both 300 mg and 600 mg. Expand
...
1
2
3
...